ESMO shared a post on X:
“The ESMO Tumor-Agnostic Classifier and Screener (ETAC-S) introduces a framework for evaluating molecularly guided therapies beyond tumor type.
Where does Liquid Biopsy fit in?
Enables non-invasive genomic profiling for tumor-agnostic therapies
Detects targetable alterations in ctDNA for real-time treatment decisions
Supports longitudinal monitoring of treatment response and resistance.
Liquid biopsy is shaping the future of molecular screening and tumor-agnostic precision oncology!
Authors: C.B. Westphalen et al.
